Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osiris/Genzyme Anticipate Approval Of Stem Cell Therapy Prochymal By 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

Submission for graft-versus-host disease indication begins under a rolling BLA this quarter, with final data due at mid-year and a possible six-month review for the first therapy of its kind.

You may also be interested in...



Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD

Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.

Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD

Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.

Osiris/Genzyme Put Stem Cells On The Deal Map

First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel